71.50

2.94% 2.04

After Hours: 71.20 -0.30 -0.42%

Novo Nordisk Adr (NVO)

Overview News Price History Option Chain Why NVO Down? Discussions Forecast Stock Split Dividend History

Novo Nordisk Adr stock is traded at $71.50, with a volume of 11.18M. It is up +2.94% in the last 24 hours and up +9.73% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Previous Close:

$69.46

Open:

$69.79

24h Volume:

11.18M

Relative Volume:

1.19

Market Cap:

$242.39B

Revenue:

$43.59B

Net Income/Loss:

$15.04B

P/E Ratio:

21.18

EPS:

3.3766

Net Cash Flow:

$10.74B

1W Performance:

+6.16%

1M Performance:

+9.73%

6M Performance:

-33.05%

1Y Performance:

-46.16%

1-Day Range:

$69.07

$71.56

1-Week Range:

$68.30

$71.56

52-Week Range:

$57.00

$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Name

Novo Nordisk Adr

Sector

Healthcare (1170)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

77,406

Twitter

@novonordisk

Next Earnings Date

2024-12-06

Latest SEC Filings

NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVO Novo Nordisk Adr	71.50	299.26B	43.59B	15.04B	10.74B	3.3766
LLY Lilly Eli Co	737.67	640.72B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	155.21	367.98B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	186.11	323.71B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	115.76	222.69B	53.22B	12.86B	14.85B	6.39

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy
Apr-12-24	Initiated	BMO Capital Markets	Outperform
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Neutral
Dec-01-23	Initiated	Cantor Fitzgerald	Overweight
Oct-02-23	Initiated	Argus	Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-15-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-28-22	Downgrade	UBS	Neutral → Sell
Jun-27-22	Upgrade	Exane BNP Paribas	Underperform → Neutral
Jun-07-22	Upgrade	JP Morgan	Neutral → Overweight
May-31-22	Upgrade	Guggenheim	Neutral → Buy
Apr-25-22	Upgrade	Cowen	Market Perform → Outperform
Apr-12-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-16-22	Upgrade	Deutsche Bank	Hold → Buy
Jan-25-22	Downgrade	Liberum	Hold → Sell
Dec-20-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-17-21	Downgrade	Deutsche Bank	Buy → Hold
Jan-20-21	Downgrade	Credit Suisse	Outperform → Neutral
Jan-15-21	Initiated	Deutsche Bank	Buy
Sep-29-20	Initiated	Berenberg	Hold
Jul-06-20	Downgrade	BofA Securities	Buy → Neutral
May-11-20	Downgrade	UBS	Buy → Neutral
May-04-20	Initiated	Cowen	Market Perform
Mar-16-20	Upgrade	BofA/Merrill	Neutral → Buy
Jan-03-20	Downgrade	Guggenheim	Buy → Neutral
Nov-18-19	Upgrade	Barclays	Equal Weight → Overweight
Sep-17-19	Upgrade	Citigroup	Neutral → Buy
Aug-30-19	Downgrade	Jefferies	Hold → Underperform
Jun-20-19	Downgrade	Deutsche Bank	Buy → Hold
Jun-11-19	Upgrade	Barclays	Underweight → Equal Weight
Apr-29-19	Upgrade	Credit Suisse	Neutral → Outperform
Jan-29-19	Initiated	Exane BNP Paribas	Outperform
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Dec-29-17	Upgrade	JP Morgan	Underweight → Neutral
Dec-06-17	Upgrade	BofA/Merrill	Neutral → Buy
Dec-01-17	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-25-17	Downgrade	Exane BNP Paribas	Outperform → Neutral
Sep-06-17	Upgrade	BofA/Merrill	Underperform → Neutral

View All

Novo Nordisk Adr Stock (NVO) Latest News

May 29, 2025

Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.

May 29, 2025

May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025

May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025

May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025

May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025

May 08, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria

May 08, 2025

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

Novo Nordisk cuts guidance but says generic competition will ease - Sharecast.com

May 07, 2025

May 06, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

Apr 30, 2025

Apr 29, 2025